Audit: QRS - Casein for Health & Longevity
Audit conducted on 18/09/2026 09:24 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol doses (30–40 g, 27.5–40 g, 150–600 mg), time-to-effect values (12 weeks, 2–8 weeks, 2–4 weeks), biomarker targets and cadence trace verbatim to the ER Therapeutic Protocol, Practical Considerations and Monitoring sections. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | No ER section is empty; cautious framing such as “no timing advantage at other times” and “predicted to fall … but mostly unchanged” is carried over. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | The at-a-glance retains “in older men only the overnight effect is shown”; contraindication severity (“at any severity”, “regardless of current test results”) is preserved unweakened. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from the ER “Populations who should avoid Casein” list, interactions from the ER interaction bullets, benefits/risks from their own tiered sections; no modifying factor is promoted. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Flat, declarative register matching the ER throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and doses paired with plain-language framing. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Statements are descriptive (“Micellar casein, 30 minutes before bed”), not prescriptive. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No “should”, “must”, or “recommended” in the document’s own voice; the footer disclaimer is the template’s. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Every cell states what the evidence shows or what the trials used. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun occurs in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to the Monitoring table, where they are the biomarker names themselves. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are single clauses; no item carries a trailing explanation. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text search for direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes biomarker testing, body-composition scanning and structured resistance training. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Nightly pre-sleep dosing, separate hydrolysate preparations and 90-minute polyphenol separation are presented without hedging on convenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Optimal functional ranges rather than conventional clinical cut-offs are used as targets. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The polyphenol-blunting interaction is surfaced as a Medium risk and as a key interaction, which matters chiefly to this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No lay route-of-administration phrasing; “micellar casein”, “casein hydrolysate”, “alpha-s1-casein hydrolysate” are used precisely and distinguished from one another. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fourteen fixed strings match the template byte for byte (lines 446, 488, 534, 567, 582, 604, 634, 638–640, 758). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template variables present: page_title, header_topic, header_subline_date, header_subline_model, at_a_glance, action_1–3 (label/value/sub), time_1–3 (label/value/sub), benefits_×4, stop_items, caution_items, risks_×4, marker_#name/target/why (8 rows), monitoring_cadence, qualitative_item# (5 items). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A line-by-line comparison against the template shows differences only inside the variable spans; CSS, structure, website-spans and footer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard pre-sleep dose”, “Resistance-training protocol” and “Hydrolysate for blood pressure” are the ER’s own bold labels (ER lines 343, 345, 351). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Protocol labels are verbatim; Monitoring marker names match the ER biomarker table entries; time-to-effect cell labels name the outcome domains the ER bullets describe, as the ER’s two bullets share one label. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters occur; the ER’s “⚠️ Conflicted” markers were correctly stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Single .sheet container at the template’s A4 print rules; all sections condensed to single-clause items within the per-section budget. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after the doctype and before the template comment at line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: casein_2026-0918-0453_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0918-0907. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file on disk: casein_2026-0918-0453_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All ten keys are single-space-separated with no trailing whitespace and no superfluous quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Casein for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Casein for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/18/2026”, matching qrs_creation_date 2026-0918-0907. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; the ER’s “Also known as” list is absent. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Four sentences mapping to the Conclusion’s four movements: what casein is, the muscle finding, the blood-pressure finding, the principal harms. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 60 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause traces to ER Conclusion lines 469–473. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “slow-digesting protein”, “derived fragments”, “artery benefit” replace the ER’s kinetic, peptide and flow-mediated-dilation vocabulary; no acronym appears. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial, author, year or sample size is named. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | “lower blood pressure slightly” carries no figure; no confidence intervals or p-values. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items map to the ER’s “Populations who should avoid Casein” list (ER lines 317–321). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Complete one-to-one coverage of the five ER avoid-populations, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Five <li> elements at lines 570–577. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s definitional gloss for eosinophilic esophagitis is stripped; no dash-trailed clause remains. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “stage 4 or worse (eGFR below 30 mL/min/1.73 m²), unless protein intake is set by a renal clinician”, “at any severity” and “regardless of current test results” are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in its contraindication bullets. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names five such populations and the section is correctly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items map to the ER’s ten interaction bullets (ER lines 295–313). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Ten for ten, with no overlap with the five contraindication entries. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Ten <li> elements at lines 585–594. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s Caution/Monitor grading, mechanism sentences and separation-interval instructions are all stripped; each item is a bare drug or supplement class. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER parenthetical drug list survives in trimmed form (e.g., “(lisinopril, losartan)”, “(doxycycline, ciprofloxacin)”, “(nitrate, potassium, magnesium, garlic, fish oil)”); none is dropped entirely. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in its interaction bullets. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names ten such interactions and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to the ER “Therapeutic Protocol” bullets at lines 343, 345, 351, with the timing note from line 353. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The standard pre-sleep dose, the resistance-training pairing that produced the trial outcome, and the distinct hydrolysate preparation — the three decisions the ER protocol turns on. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Nine of nine cells populated; values 30–40 g, 27.5–40 g nightly and the separate hydrolysate preparation at 150–600 mg all match the ER. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Muscle size and strength, blood pressure and sleep, drawn from ER Practical Considerations lines 400 and 402. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Muscle (High tier) then blood pressure (High tier) then sleep (Medium tier), matching the ER’s benefit ordering. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Nine of nine cells populated; 12 weeks, 2–8 weeks and 2–4 weeks match the ER’s “12 weeks”, “two to eight weeks” and “two weeks and four weeks”. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All nine entries correspond to the nine ER benefit headings across the four tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (lines 536–560). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER benefit heading alone; the ER’s “Magnitude” figures, meta-analysis references and “⚠️ Conflicted” markers are all stripped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits entry; the ER’s CPP-ACP gloss is reduced to “remineralization of early enamel lesions”. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry ER content. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eight entries correspond to the eight ER risk headings across the four tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (lines 606–628). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER risk heading alone; odds ratios, funding disclosures and the “⚠️ Conflicted” marker on the A1 beta-casein item are stripped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks entry; the ER’s IGF-1 and anaphylaxis glosses are removed. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry ER content. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Marker names, targets and rationales are taken from the ER biomarker table at lines 432–441. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarkers present: blood pressure, lean body mass, grip strength, fasting insulin, IGF-1, eGFR, hs-CRP, casein-specific IgE, with targets matching (105–120 / 65–78 mmHg, ≥40 kg men / ≥25 kg women, 2–5 µIU/mL, ≥90 mL/min/1.73 m², <1.0 mg/L, below 0.35 kU/L). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 748: weekly for the first month after adding a hydrolysate, then every 3–6 months; body composition and grip strength at 12 weeks then every 6–12 months; insulin, IGF-1, eGFR and hs-CRP annually — matching ER line 430. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five items map to the ER’s qualitative marker list at lines 445–449. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Sleep onset and night wakings, morning appetite, bloating/gas/stool consistency, perceived recovery and soreness, training progression — five for five. |
Issues 18/09/2026 09:24
Pass rate 100.00%. No issues found.
Issues 18/09/2026 09:17
- 4.5 — Content exceeds one A4 page: Estimated rendered height is roughly 1.8 A4 pages; the largest overruns are the 10-item Key Interactions gate with full example-drug lists in a half-width column (lines 586–600), the 8-row Monitoring table with multi-line targets (lines 669, 706, 746) plus a 3-line cadence (lines 755–757), and the 157-character
action_3_subcell (lines 481–482).
Fixes 18/09/2026 09:17
- 4.5 — Key Interactions drug lists trimmed: Shortened the parenthetical example-drug lists to two or three representative agents each (e.g. “lisinopril, ramipril, losartan, valsartan” → “lisinopril, losartan”; “beetroot nitrate, potassium, magnesium, garlic extract, fish oil” → “nitrate, potassium, magnesium, garlic, fish oil”) and dropped “Over-the-counter” from the antacid item, keeping all ten interactions while cutting roughly four wrapped lines from the gate.
- 4.5 — Protocol and time-to-effect cells condensed:
action_3_subcut from 157 to 108 characters (“distinct from intact casein powder, at the doses used in the blood-pressure trials” → “not intact casein powder, at the trial doses”) andtime_1_subreduced to “Nightly use plus training; the overnight synthesis effect is immediate”. - 4.5 — Monitoring targets and cadence shortened:
marker_2_target→ “No absolute target; stable or rising from own baseline”,marker_5_target→ “Mid-range of the lab’s age- and sex-specific interval”,marker_8_why→ “Identifies the one contraindicated population”, and the cadence rewritten with numeric intervals (“every 3–6 months”, “every 6–12 months”). - 4.5 — Contraindication threshold compacted: Third stop item changed to “Chronic kidney disease stage 4 or worse (eGFR below 30 mL/min/1.73 m²), unless protein intake is set by a renal clinician”, preserving the staging and threshold qualifiers.
- 4.5 — Qualitative items tightened: Removed the trailing relative clauses from items 1, 2, 3 and 5 (e.g. “which is the practical version of the strength endpoint” → “the practical version of the strength endpoint”) without dropping any of the five ER markers.
Issues 18/09/2026 09:11
- 10.2 — Protocol cell duplicates timing: The third Protocol cell “Best time of day / Evening / 30 minutes before sleep” (QRS lines 470–483) repeats the timing already carried by cell 1 (“Micellar casein, 30 minutes before bed”, line 456) instead of covering a distinct aspect, while the ER’s “Hydrolysate for blood pressure” bullet — the only actionable route to one of the two High-tier benefits — is absent from the panel.
Fixes 18/09/2026 09:11
- 10.2 — Third Protocol cell made distinct: Replaced the duplicated “Best time of day / Evening / 30 minutes before sleep” cell with the ER’s “Hydrolysate for blood pressure” bullet (value “Separate preparation”; sub noting the hydrolysate is distinct from intact casein powder and that the sleep hydrolysate is dosed separately at 150–600 mg), and folded “no timing advantage at other times” into the first cell’s sub so no timing information was lost.